The FDA approved bevacizumab-maly (Alymsys, Amneal Pharmaceuticals), a biosimilar to bevacizumab (Avastin, Genentech), for the treatment of several types of cancer.
The vascular endothelial growth factor inhibitor is the third bevacizumab biosimilar to be approved in the United States, following bevacizumab-bvzr (Zirabev, Pfizer) in 2019 and bevacizumab-awwb (Mvasi, Amgen) in 2017.